Detailed results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer were presented this week. As expected, the combination of the two drugs reduced the risk of tumor progression in patients with recurrent ovarian cancer. The good news is those results included the ‘hardest-to-treat’ patients no longer responding to platinum-based chemotherapy. The bad news is the study doesn't yield enough data to make a convincing case for fosbretabulin's approval. Phase II study enrolled 107 patients with recurrent ovarian cancer, and randomized them to treatment with the combination of fosbretabulin and Avastin, or Avastin alone. The study achieved a 31% reduction in the risk of tumor progression or death favoring the combination of both as opposed to just Avastin. Recurrent ovarian cancer patients benefit from the combination, and the benefit is particularly promising in the hardest-to-treat patients with platinum-resistant tumors.